Mobile

A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppressio...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-015509-38

A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, noninfectious, intermediate, posterior, or panuveitis requiring immunosuppression (INSURE Study)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of continuous treatment with subcutaneous AIN457 compared to placebo for maintaining quiescence of intraocular inflammation and the prevention of active intermediate, posterior or panuveitis recurrences in adults with non-infectious, uveitis affecting the posterior segment.

Critère d'inclusion

  • Non-infectious, intermediate uveitis, posterior uveitis or panuveitis

Liens